Effects of NR1H3 genetic variation on the expression of liver X receptor α and the progression of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Natunen, Teemu ^a,b   Martiskainen, Henna ^a,b   Sarajar̈vi, Timo ^a,b   Helisalmi, Seppo ^a,b   Pursiheimo, Juha Pekka ^c   Viswanathan, Jayashree ^a,b   Laitinen, Marjo ^a,b   Mak̈inen, Petra ^a,b   Kauppinen, Tarja ^a,b   Rauramaa, Tuomas ^a,b   Leinonen, Ville ^a,b   Alafuzoff, Irina ^d   Haapasalo, Annakaisa ^a,b   Soininen, Hilkka ^a,b   Hiltunen, Mikko ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BETA SECRETASE; DNA; LIVER X RECEPTOR ALPHA; MESSENGER RNA; AMYLOID BETA PROTEIN; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; SECRETASE; TAU PROTEIN;

ABCA1 GENE; ABCG1 GENE; AGED; ALLELE; ALZHEIMER DISEASE; APOE GENE; APOE4 GENE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INFERIOR TEMPORAL CORTEX; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; NR1H3 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; CEREBROSPINAL FLUID; DEMOGRAPHY; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; SOLUBILITY; TEMPORAL LOBE; VERY ELDERLY;

AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; APOLIPOPROTEIN E4; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; ORPHAN NUCLEAR RECEPTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; SOLUBILITY; TAU PROTEINS; TEMPORAL LOBE;

EID: 84894248845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080700     Document Type: Article

References (50)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368: 387-403. (Pubitemid 44108123)
2. De Strooper B, Annaert W (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 113 (Pt 11): 1857-1870. (Pubitemid 30386490)
3. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, et al. (2010) Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330: 1774.
4. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, et al. (2013) Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5: 189ra77.
5. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Aβ peptide: The many roads to perdition. Neuron 43: 605-608. (Pubitemid 39179722)
6. Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, et al. (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 58: 681-693.
7. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, et al. (2006) Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26: 4985-4994. (Pubitemid 44315280)
8. Mahley RW, Rall Jr SC (2000) Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537.
9. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein e and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9: 106-118.
10. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, et al. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3: 89ra57.
11. Beaven SW, Tontonoz P (2006) Nuclear receptors in lipid metabolism: Targeting the heart of dyslipidemia. Annu Rev Med 57: 313-329. (Pubitemid 43261994)
12. Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, et al. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335: 1503-1506.
13. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, et al. (2010) ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 285: 34144-34154.
14. Fitz NF, Cronican AA, Lefterov I, Koldamova R (2013) Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science 340: 924-c.
15. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, et al. (2013) Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340: 924-d.
16. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, et al. (2013) Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340: 924-e.
17. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, et al. (2013) Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340: 924-f.
18. Natunen T, Helisalmi S, Vepsäläinen S, Sarajärvi T, Antikainen L, et al. (2012) Genetic analysis of genes involved in amyloid-β degradation and clearance in Alzheimer's disease. J Alzheimer's Dis 28: 553-559.
19. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112: 389-404. (Pubitemid 44469160)
20. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
21. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43: 429-436.
22. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
23. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, et al. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853-862. (Pubitemid 29426831)
24. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, et al. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866.
25. Wang J, Dickson DW, Trojanowski JQ, Lee VMY (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158: 328-337. (Pubitemid 29382824)
26. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) β-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389. (Pubitemid 35014802)
27. Holsinger RMD, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann Neurol 51: 783-786. (Pubitemid 34568861)
28. Li R, Lindholm K, Yang LB, Yue X, Citron M, et al. (2004) Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101: 3632-3637. (Pubitemid 38338246)
29. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ (2002) α- And β-secretase: Profound changes in Alzheimer's disease. Biochem Biophys Res Commun 299: 373-376. (Pubitemid 35365637)
30. Yang LB, Lindholm K, Yan R, Citron M, Xia W, et al. (2003) Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease [1]. Nat Med 9: 3-4. (Pubitemid 36098241)
31. Galasko D, Chang L, Motter R, Clark CM, Kaye J, et al. (1998) High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937-945. (Pubitemid 28335112)
32. Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, et al. (2007) CSF Aβ42, tau and phosphorylated tau, APOE ε4 allele and MCI type in progressive MCI. Neurobiol Aging 28: 507-514.
33. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, et al. (2009) Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66: 382-389.
34. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-144.
35. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, et al. (1993) Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90: 9649-9653. (Pubitemid 23315843)
36. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al. (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131.
37. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K (2004) APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42. Neurology 62: 2116-2118. (Pubitemid 38738236)
38. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol Brain Res 33: 174-178.
39. Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, et al. (1999) Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res 843: 87-94. (Pubitemid 29488698)
40. Glöckner F, Meske V, Ohm TG (2002) Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. Neuroscience 114: 1103-1114.
41. Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, et al. (2000) Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis 7: 23-37. (Pubitemid 30141817)
42. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, et al. (2007) Expression of APP pathway mRNAs and proteins in alzheimer's disease. Brain Res 1161: 116-123. (Pubitemid 47068429)
43. Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE (2010) APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet 153B: 409-417.
44. Yamada T, Kondo A, Takamatsu JI, Tateishi J, Goto I (1995) Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease. J Neurol Sci 129: 56-61.
45. Yamagata K, Urakami K, Ikeda K, Ji Y, Adachi Y, et al. (2001) High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 12: 57-62. (Pubitemid 32149708)
46. Tontonoz P, Mangelsdorf DJ (2003) Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17: 985-993. (Pubitemid 36683707)
47. Zelcer N, Tontonoz P (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614. (Pubitemid 43326865)
48. Cao G, Bales KR, DeMattos RB, Paul SM (2007) Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: Relevance to Alzheimer's disease therapeutics. Curr Alzheimer Res 4: 179-184. (Pubitemid 46557508)
49. Mandrekar-Colucci S, Landreth GE (2011) Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets 15: 1085-1097.
50. Ou Z, Wada T, Gramignoli R, Li S, Strom SC, et al. (2011) MicroRNA hsa-miR-613 targets the human LXRαgene and mediates a feedback loop of LXRα autoregulation. Mol Endocrinol 25: 584-596.